# PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

> **NCT01070550** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 4680 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a (Pegasys®)

## Key facts

- **NCT ID:** NCT01070550
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 4680 (ACTUAL)
- **Last updated:** 2016-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01070550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01070550, "PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01070550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*